The American Society of Breast Surgeons supports annual screening mammography for women age 40 and older. Numerous studies have demonstrated that screening mammography leads to improved survival due to earlier detection of breast cancer, including in women age 40-49. While mammography is less sensitive in younger women and in women with dense breast tissue, the use of digital mammography improves the rate of detection in these women. Some breast cancers will be missed due to breast density or other factors, and some patients will undergo additional imaging or even biopsy for lesions that are subsequently found not to be malignant. However despite the limitations, screening mammography remains the most cost-effective, practical, and accurate screening tool available for the early detection of breast cancer at this time. Patients with breast cancers detected in an earlier stage are more likely to be candidates for breast-conserving surgery, less likely to require chemotherapy, and will have an improved survival compared to women who have their cancers diagnosed at a later stage. Women should be aware of their risk factors and should discuss their concerns regarding screening mammography with their physician.
Obstetrics and Gynecology
Advanced Practice Nurses
To provide recommendations concerning annual screening mammography for women age 40 and older
Women age 40 and older
Annual screening mammography for women age 40 and older
- Earlier detection of breast cancer
- Improved survival rates
Searches of Electronic Databases
- A medical librarian conducted a database search (MEDLINE/PubMed - US National Library of Medicine)
- The time frame of the literature search(es) was between June and July of 2011.
- There were no specific inclusion/exclusion criteria. The librarian researched mammography screening articles both from published literature as well as other medical specialty society position statements.
- Specific search terms used included "mammogram," "screening," and "guidelines."
A formal cost analysis was not performed and published analyses were not reviewed.
Internal Peer Review
This position statement was approved on August 15, 2011 by the American Society of Breast Surgeons Board of Directors.
The type of evidence supporting the recommendations is not specifically stated.
Patients with breast cancers detected in an earlier stage are more likely to be candidates for breast-conserving surgery, less likely to require chemotherapy, and will have an improved survival compared to women who have their cancers diagnosed at a later stage.
Mammography is less sensitive in younger women and in women with dense breast tissue.
An implementation strategy was not provided.
|American Society of Breast Surgeons. Position statement on screening mammography. Columbia (MD): American Society of Breast Surgeons; 2011 Aug 15. 1 p. [4 references]|
Not applicable: The guideline was not adapted from another source.
2011 Aug 15
American Society of Breast Surgeons - Professional Association
The American Society of Breast Surgeons
Board of Directors, The American Society of Breast Surgeons
This is the current release of the guideline.
Electronic copies: Available in Portable Document Format (PDF) from the American Society of Breast Surgeons Web site .
The following is available:
- Position statement on screening mammography. Video statement press release and video. Available from the American Society of Breast Surgeons Web site .
This NGC summary was completed by ECRI Institute on April 15, 2013. The information was verified by the guideline developer on May 13, 2013.
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.
The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.